Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Macular Degeneration

• Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
• Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
• Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
• Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
• A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
• Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
• A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
• A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular
• Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
• Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
• Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
• Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
• Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
• A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
• Cool vs Room-temperature Artificial Tears
• A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
• Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
• Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
• Efficacy and Safety of RC28-E Versus Aflibercept
• Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
• Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME
• Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy
• Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
• Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85
• Safety and Tolerability Trial of KH631 Gene Therapy for Neovascular AMD
• A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
• Associations Between the Oral and Intestinal Icrobiome and Neovascular Age-related Macular Degeneration
• Safety Study of Zimura™in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
• Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera
• A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration
• QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration
• The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
• Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
• QA102 Phase II Study in Subjects With Dry AMD
• Open-Label Extension for Subjects Who Previously Completed Phase 3 Study ISEE2008.
• Effect of Corona Virus on Intravitreal Injections
• This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
• A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
• TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration
• Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
• A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
• A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME).
• Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
• A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
• A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
• Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
• Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
• This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
• Targeted Fluorescence Imaging in AMD
• Study of Application of Pulse Electrical Stimulation Around Eye in Age-related Macular Degeneration
• Adjunct Episcleral Brachytherapy for PCV
• Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1
• A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
• Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to dAMD
• Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
• Clinical Study on the Efficacy and Safety of BAT5906 Injection
• A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
• Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
• A Study to Evaluate the Safety and Efficacy of RQC for AMD
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
• Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration
• Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD
• Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
• Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
• A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
• Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
• Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
• RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
• QA102 Phase 1 Study in Healthy Young and Older Adult Subjects
• Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
• BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration
• A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
• Non-Responsive Diabetic Macular Edema and Spironolactone
• A Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab
• A Study of IBI302 in Patients With nAMD
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
• Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
• FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment
• First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
• Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
• ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
• A Phase 3 Two-part Study of the Efficacy and Safety of HLX04-O in Subjects With Wet Age-related Macular Degeneration
• Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
• Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
• Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
• Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD
• A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
• Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
• A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
• A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
• Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
• A Study Assessing the Long-Term Safety and Tolerability of FHTR2163 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
• An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
• A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
• Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients
• A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）
• Study of RO7250284 in Participants With Neovascular Age-Related Macular Degeneration
• HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
• The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
• Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
• Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
• Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
• RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
• MMP-9 Inhibition for Recalcitrant Wet AMD
• Study of STG-001 in Subjects With Stargardt Disease
• A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects
• A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
• The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
• A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
• EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
• A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
• Study to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensit
• Effect of Intravitreally Administered AIV007 in Subjects With nAMD
• Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
• Sildenafil for Treatment of Choroidal Ischemia
• Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
• A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
• Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
• Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
• Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
• A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
• Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
• Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
• A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
• A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
• A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
• Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
• Treat and Extend Analysis Trial With Aflibercept in Wet-AMD
• The Sahlgrenska Anti-VEGF Study
• Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
• A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
• Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
• A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
• A Study Assessing the Safety, Tolerability, and Efficacy of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
• A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
• Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
• Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
• Post Intravitreal Injection Topical NSAID vs. Patching
• A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
• A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
• Phase 3 Study of ALK-001 in Geographic Atrophy
• A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
• GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
• A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
• Effect Aflibercept on Ocular Perfusion
• Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
• Safety and Efficacy of Emixustat in Stargardt Disease
• Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration
• JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients
• Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
• Safety and Tolerability of Oral CM082 in Patients With wAMD
• Extension Study for the Port Delivery System With Ranibizumab (Portal)
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
• RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
• CLN-0046: Treatment of AMD Subjects With OTX-TKI
• A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
• Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
• Intense Treatment Regimen With Intravitreal Aflibercept Injection
• AAVCAGsCD59 for the Treatment of Wet AMD
• Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections
• Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration
• Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration
• Single or Combined Protocols for NV-AMD
• A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
• A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
• Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
• Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD
• Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
• Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
• Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
• Pegcetacoplan (APL-2) in Neovascular AMD
• Carbidopa-Levodopa in Dry AMD With Geographic Atrophy
• Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
• Ziv-aflibercept Efficacy in Better Regulating AMD
• SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
• Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
• A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration
• Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
• Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
• ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
• Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
• Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
• The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD
• Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
• A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
• Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA
• Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
• Clinical Study of Transplanting Human Retinal Pigment Epithelial Cells for Treatment of Macular Degeneration
• Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
• A Study of the Safety and Tolerability of ASP7317 in Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
• Intravitreal Aflibercept for Submacular Hemorrhage
• A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
• An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
• Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
• Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab
• Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept
• Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
• Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
• Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
• Dose Ranging Study of Carbidopa-levodopa
• Carbidopa-levodopa in Neovascular AMD
• The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
• A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration
• Episcleral Brachytherapy for the Treatment of Wet AMD
• Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
• "Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study
• Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
• Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
• Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
• Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
• A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
• Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
• Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
• Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
• An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
• Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
• Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
• Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
• Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
• Ocular Discomfort Assessment After Intravitreal Injections
• Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
• Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
• Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
• Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
• Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
• Cytokeratin 8 Level in Age-related Macular Degeneration
• A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
• EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
• Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
• Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
• PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
• Aflibercept in Recurrent or Persistent CNV
• A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
• CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
• Alpha Lipoic Acid in Geographic Atrophy
• Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
• An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Ma
• Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy
• Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
• Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
• Head to Head Study of Anti-VEGF Treatment.
• Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
• Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
• Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD
• Intravitreal Injections of Ziv-aflibercept for Macular Diseases
• A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
• Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen
• Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
• Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
• Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
• To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
• Study of DS-7080a for the Treatment of Macular Degeneration
• Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
• Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
• Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
• Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
• A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
• IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
• Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
• Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
• Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
• Phase 1 Study of CM082 in Patients With wAMD
• Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration
• VITAL - Individualising Therapy for Neovascular AMD With Aflibercept
• Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
• Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
• Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
• A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
• A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
• Geographic Atrophy and Intravitreal Ranibizumab Injections
• Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
• LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
• X-82 to Treat Age-related Macular Degeneration
• Treatment -Resistant Neovascular Age-Related Macular Degeneration
• Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
• Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.
• Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD
• A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
• Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
• Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
• Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
• Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
• Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
• Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
• Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
• Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
• Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
• A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
• A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
• Stereotactic Radiotherapy for Wet AMD (STAR)
• Phase 1 Safety Study of ALK-001 in Healthy Volunteers
• Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
• Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
• Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
• Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
• A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
• A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
• A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
• A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
• Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I
• Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
• Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
• Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
• Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
• Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
• Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
• A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
• Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
• Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
• A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
• Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
• Aflibercept in Polypoidal Choroidal Vasculopathy
• Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
• An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)
• A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
• First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration
• Analysis of Aqueous and Vitreous Humor
• Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
• Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
• Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
• Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
• Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
• A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration
• Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration
• Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
• Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
• Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
• Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
• Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
• Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
• Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
• Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
• Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
• A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
• Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
• Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
• Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
• Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
• Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
• Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
• Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
• Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
• ESBA1008 Microvolume Study
• Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
• Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
• Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
• Effects of Sildenafil on Choroidal Thickness in AMD
• Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
• Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
• Efficacy and Safety Study of ESBA1008 Versus EYLEA®
• Eylea Post Marketing Surveillance(PMS)
• Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)
• Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
• Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
• Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
• Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
• Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
• EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
• EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
• A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration
• Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
• A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes
• Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
• Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
• Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
• Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
• A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
• Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
• Pilot Study of X-82 in Patients With Wet AMD
• On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
• Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
• Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
• Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
• Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
• Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
• Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
• Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
• Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
• A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
• Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
• Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora
• Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
• Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
• Lucentis KAV Study
• Study for Recalcitrant Age Related Macular Degeneration
• Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
• Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
• Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
• Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
• FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
• Safety and Tolerability Study for Age-Related Macular Degeneration
• VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
• Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
• Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
• Study EvAluating Genotypes While Using Lucentis 2
• Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing
• Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany
• Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
• Sirolimus for Advanced Age-Related Macular Degeneration
• An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
• Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
• Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
• Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
• A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
• Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
• Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
• 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
• Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
• iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
• Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
• Ranibizumab and the Risk of Arterial Thromboembolic Events
• Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
• Bevacizumab for Neovascular Age-related Macular Degeneration
• Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
• Ozurdex for Macular Edema Post Membrane Peeling
• Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
• Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
• Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
• Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
• Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
• OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
• Intravitreal Injection Anesthesia - Comparison of Different Topical Agents
• Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
• ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
• HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
• Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)
• Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD
• 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
• French Evaluation Group Avastin Versus Lucentis
• Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration
• Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
• A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
• Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
• Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
• Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
• LUCAS (Lucentis Compared to Avastin Study)
• Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
• A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
• A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
• A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
• A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans
• Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
• Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
• Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration
• Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
• A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
• Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
• Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
• A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
• Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
• Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
• Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
• WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
• Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
• Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
• A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
• Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
• Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
• Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization
• Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
• Lucentis in Advanced Macular Degeneration
• Supplemental Adjuvants for Intracellular Nutrition and Treatment
• A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
• Geographic Atrophy Treatment Evaluation
• Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab
• Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
• The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
• Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
• Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
• Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
• Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
• Combined Therapy in Age-Related Macular Degeneration (ARMD)
• Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
• Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab
• A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
• ERG/EOG Study in AMD Patients Treated With Ranibizumab
• Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
• S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000
• A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
• Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
• Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
• Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
• Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
• Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
• Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
• An Extension to Study MD7108240
• Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
• VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
• Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
• Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
• Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
• Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
• Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
• Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
• Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
• The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
• ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
• An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects
• Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-Related Macular Degeneration
• Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)
• Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy
• Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
• Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
• Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser
• Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops
• Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
• The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
• Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
• Alprostadil in Maculopathy Study (AIMS)
• To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
• Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
• The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
• Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
• Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
• Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
• Photodynamic and Pharmacologic Treatment of CNV
• Retaane® in Age-Related Macular Degeneration
• A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
• The Zeaxanthin and Visual Function Study
• Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
• Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
• Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
• A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
• Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
• Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
• Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
• Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
• A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
• Evaluation of Dosing Interval of Higher Doses of Ranibizumab
• MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen
• Systemic Avastin Therapy in Age-Related Macular Degeneration
• Ranibizumab and Reduced Fluence PDT for AMD
• Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
• Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
• Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
• Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
• Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
• Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
• CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
• Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
• Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
• The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)
• Study Evaluating Genotypes Using Lucentis
• Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
• Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
• Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
• EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
• A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
• Scotoma Reduction in AMD Patients Treated With Ranibizumab
• Copaxone in Age Related Macular Degeneration
• TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
• A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
• Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
• Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
• Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD
• A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
• A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
• Combination Therapy for Neovascular Age Related Macular Degeneration
• Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
• Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
• Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
• Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
• Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
• Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
• Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
• A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
• Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)
• Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
• Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
• Efficacy of Retreatments With Intravitreal Bevacizumab
• Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
• Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
• Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.
• A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
• Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
• The Avastin vs Visudyne for Neovascular AMD Study
• Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
• An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
• Combination Therapy for Age-Related Macular Degeneration.
• An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
• Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
• Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
• A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
• Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
• A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
• Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate
• Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
• Intravitreal Bevacizumab for Age-Related Macular Degeneration
• A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
• Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy
• Age-Related Eye Disease Study 2 (AREDS2)
• Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
• Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
• A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
• SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
• An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
• Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
• A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
• Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
• A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
• A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion
• OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
• Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
• Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
• Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
• Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
• Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
• Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
• Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
• A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
• A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
• Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
• Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
• Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
• Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.
• Treatment of Age-Related Macular Degeneration With Anecortave Acetate
• Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
• Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
• Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
• Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
• Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
• A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
• Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
• Photodynamic Therapy in Occult-Only Lesions (POOL)
• Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
• Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
• Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
• Visudyne® in Occult (VIO)
• Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
• Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease
• Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
• Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
• Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
• MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)
• A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
• A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
• Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
• Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
• Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
• Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
• A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
• Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy
• An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
• A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
• Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
• Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
• Laser and Medical Treatment of Diabetic Macular Edema
• Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
• Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
• A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
• Phase II/III Study of Anti-VEGF in Neovascular AMD
• Fluocinolone Implant to Treat Macular Degeneration
• Lutein for Age-Related Macular Degeneration
• Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
• Randomized Trials of Vitamin Supplements and Eye Disease
• Randomized Trial of Beta-Carotene and Macular Degeneration